Results from the POETIC trial, the largest trial in the world of its kind, suggest that testing women’s response to hormone therapy for breast cancer given around the time of surgery could be a fast and cheap way of predicting how likely the disease is to come back, according to results published in The Lancet Oncology.

During the COVID-19 pandemic, The Royal Marsden took a leading role in delivering urgent cancer treatment, particularly surgery. 

A pioneering lung cancer study has highlighted important factors that will need to be considered in the next wave of precision medicine studies particularly in treating genomically complicated cancers.

Clinicians from The Royal Marsden NHS Foundation Trust are joining forces with other trusts and leading industrial partners across the UK to improve the diagnosis of lung cancer and other thoracic diseases using artificial intelligence.

Results from the first ever randomised clinical trial in advanced anal cancer patients, led and supported by The Royal Marsden NHS Foundation Trust and Cancer Research UK, in collaboration with colleagues in the US, Norway and Australia, has led to a practice changing milestone with a new approach to treatment which is safer and more effective than previously recommended treatments for this group of patients.

A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the UK, Germany and US.

A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease.

Genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease, a new pilot study shows.

The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.